Diabetologia

, Volume 55, Issue 12, pp 3399–3400

Erratum to: Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials

Authors

    • Department of Primary Care Health SciencesUniversity of Oxford
  • R. Ali
    • Cancer Epidemiology UnitUniversity of Oxford
  • C. R. Bankhead
    • Department of Primary Care Health SciencesUniversity of Oxford
  • M. A. Bethel
    • Diabetes Trials Unit, Oxford Centre for Diabetes Endocrinology and MetabolismUniversity of Oxford
  • B. J. Cairns
    • Cancer Epidemiology UnitUniversity of Oxford
  • R. P. Camisasca
    • TGRD Europe, Takeda Pharmaceutical Company
  • F. L. Crowe
    • Cancer Epidemiology UnitUniversity of Oxford
  • A. J. Farmer
    • Department of Primary Care Health SciencesUniversity of Oxford
  • S. Harrison
    • Department of Primary Care Health SciencesUniversity of Oxford
  • J. A. Hirst
    • Department of Primary Care Health SciencesUniversity of Oxford
  • P. Home
    • ICM–Diabetes, The Medical SchoolNewcastle University
  • S. E. Kahn
    • Division of Metabolism, Endocrinology and Nutrition, Department of MedicineVeterans Affairs Puget Sound Health Care System and University of Washington
  • J. H. McLellan
    • Department of Primary Care Health SciencesUniversity of Oxford
  • R. Perera
    • Department of Primary Care Health SciencesUniversity of Oxford
  • A. Plüddemann
    • Department of Primary Care Health SciencesUniversity of Oxford
  • A. Ramachandran
    • India Diabetes Research FoundationDr A. Ramachandran’s Diabetes Hospitals
  • N. W. Roberts
    • Department of Primary Care Health SciencesUniversity of Oxford
  • P. W. Rose
    • Department of Primary Care Health SciencesUniversity of Oxford
  • A. Schweizer
    • Novartis Pharma
  • G. Viberti
    • Unit for Metabolic Medicine, School of MedicineKing’s College London
  • R. R. Holman
    • Diabetes Trials Unit, Oxford Centre for Diabetes Endocrinology and MetabolismUniversity of Oxford
Erratum

DOI: 10.1007/s00125-012-2740-9

Cite this article as:
Stevens, R.J., Ali, R., Bankhead, C.R. et al. Diabetologia (2012) 55: 3399. doi:10.1007/s00125-012-2740-9

Erratum to: Diabetologia

DOI 10.1007/s00125-012-2653-7

The authors regret a single data transcription error at the co-ordinating centre that resulted in numerical errors in several of the reported hazard ratios for all-cause mortality. The correct values (shown in red font) in the text should have been:

Abstract: The summary RR for all-cause mortality was https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figa_HTML.gif (95% CI https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figb_HTML.gif , https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figc_HTML.gif ) across all trials.

Results, All-cause mortality: RRs for all-cause mortality could be obtained for 13 trials, representing 66,447 person-years of follow-up during which https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figd_HTML.gif deaths were recorded. … The summary RR for all-cause mortality in people randomised to metformin compared with all comparators was https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Fige_HTML.gif (95% CI https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figf_HTML.gif , https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figg_HTML.gif ). The summary RR for all-cause mortality was 0.91 (95% CI 0.70, 1.18) in trials comparing metformin to placebo/usual care and https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figh_HTML.gif (95% CI https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figi_HTML.gif , https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figj_HTML.gif ) in trials comparing metformin to active comparators (Fig. 3). The summary RR from 1-year trials was 0.84 (95% CI 0.52, 1.38) and the summary RR from trials longer than 1 year was https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figk_HTML.gif (95% CI https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figl_HTML.gif , https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figm_HTML.gif ). In a post hoc sensitivity analysis, excluding the UKPDS sulfonylurea trial had the effect of reducing the RR for all-cause mortality in metformin compared with placebo/usual care to 0.67 (95% CI 0.49, 0.93; I2 0.0%), and in metformin compared with any comparator to https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Fign_HTML.gif (95% CI https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figo_HTML.gif , https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Figp_HTML.gif ; I2 0.0%).
https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2740-9/MediaObjects/125_2012_2740_Fig1_HTML.gif
Fig. 3

RRs (squares) and 95% CIs (horizontal bars) for all-cause mortality in participants in RCTs randomised to metformin compared with comparators, stratified by comparator type, with summary estimates and 95% CIs (diamonds). aNote that the ADOPT-G and ADOPT-R lines represent multiple comparisons from a single trial, and the analysis takes account of correlation between these comparisons: see original text for details

A corrected version of Fig. 3 is shown above.

In addition, a typographical error appeared in Fig. 2. In the ‘Study’ column ‘EDIT-A [43]’ should have read ‘EDIT [43]’.

Copyright information

© Springer-Verlag Berlin Heidelberg 2012